Structure Therapeutics Inc.

Health Care
Biotechnology: Pharmaceutical Preparations
www.structuretx.com

Market Cap $4.09B
PE -33
Debt -
Cash $169.51M
EV -
FCF -$117.93M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$122.53M
EBIT	-$122.22M
ROE	-14%
ROA	-14%
FCF	-$117.93M
Equity	$864.84M
Growth Stability	1
PE	-33.41
PB	4.73
P/FCF	-34.72
Price/Cash	0.04
Equity CAGR	143%
Earnings Growth YoY	49%

Earnings Growth QoQ	7%
Equity CAGR 5Y	143%
Equity CAGR 3Y	143%
Market Cap	$4.09B
Assets	$903.33M
Cash	$169.51M
Shares Outstanding	157.92M
Working Capital	855.19M
Current Ratio	24.74
Shares Growth 3y	44%
Equity Growth QoQ	-4%
Equity Growth YoY	91%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing oral treatments for chronic metabolic and pulmonary conditions. It develops oral small molecule therapeutics for the treatment of various diseases, including those impacting the metabolic, cardiovascular, and pulmonary systems. Its initial focus is on G-protein-coupled receptors as a therapeutic target class. It is developing GSBR-1290, its oral small molecule product candidate targeting the validated glucagon-like-peptide-1 receptor for the treatment of type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases. Specifically, it is advancing ANPA-0073, its biased agonist, targeting the apelin receptor. It is also developing LTSE-2578, an investigational oral small molecule LPA1R antagonist for the treatment of idiopathic pulmonary fibrosis.

SEC Filings

Direct access to Structure Therapeutics Inc. (GPCR) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31

Sector Comparison

How does Structure Therapeutics Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Structure Therapeutics Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Structure Therapeutics Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Structure Therapeutics Inc..

Years

Calculation mode

= -$1.2B

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	-$118M	-$118M	-$118M	-$118M	-$118M	-$118M	-$118M	-$118M	-$118M	-$118M	-$118M	-$1.2B
DCF		-$107M	-$97M	-$89M	-$81M	-$73M	-$67M	-$61M	-$55M	-$50M	-$45M	-$455M
Value	-$1.2B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2022	12/2023	12/2024	TTM
Net Margins	-	-	-	-
ROA	-	-19%	-14%	-14%
ROE	-	-20%	-14%	-14%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2022	12/2023	12/2024	TTM
Debt over FCF	-	-	-	-
Debt over Equity	-	-	-	-
Growth Stability	-	-	-	1

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Neutral Debt/Equity ratio (-)

The company has a balance between equity and debt that is not too good nor too bad.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2022	12/2023	12/2024	CAGR 5Y
Revenue YoY growth	-	-	-	-
Earnings YoY growth	-	70%	37%	-
Equity YoY growth	-	-493%	91%	143%
FCF YoY growth	-	76%	44%	-